Literature DB >> 9268967

Physiological profiles of elite off-road and road cyclists.

R L Wilber1, K M Zawadzki, J T Kearney, M P Shannon, D Disalvo.   

Abstract

There are minimal scientific data describing international caliber off-road cyclists (mountain bikers), particularly as they compare physiologically with international caliber road cyclists. Elite female (N = 10) and male (N = 10) athletes representing the United States National Off-Road Bicycle Association (NORBA) Cross-Country Team were compared with elite female (N = 10) and male (N = 10) athletes representing the United States Cycling Federation (USCF) National Road Team. Submaximal and maximal exercise responses were evaluated during the "championship" phase of the training year when athletes were in peak condition. All physiological tests were conducted at 1860 m. Among the female athletes, physiological responses at lactate threshold (LT) and during maximal exercise (MAX) were similar between NORBA and USCF cyclists with two exceptions: 1) USCF cyclists demonstrated a significantly greater (P < 0.05) absolute (16%) and relative (10%) maximal aerobic power, and 2) MAX heart rate was significantly higher (P < 0.05) for the USCF athletes (6%). Among the male athletes, physiological responses at LT and MAX were similar between NORBA and USCF cyclists with two exceptions: 1) USCF cyclists produced significantly greater (P < 0.05) absolute (18%) and relative (16%) power at LT, and 2) USCF cyclists produced significantly greater (P < 0.05) absolute (12%) and relative (10%) power at MAX. These data suggest that, in general, elite off-road cyclists possess physiological profiles that are similar to elite road cyclists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268967     DOI: 10.1097/00005768-199708000-00015

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  15 in total

1.  Physiological Demands of Simulated Off-Road Cycling Competition.

Authors:  Gerhard Smekal; Serge P von Duvillard; Maximilian Hörmandinger; Roland Moll; Mario Heller; Rochus Pokan; David W Bacharach; Linda M LeMura; Paul Arciero
Journal:  J Sports Sci Med       Date:  2015-11-24       Impact factor: 2.988

Review 2.  The science of cycling: factors affecting performance - part 2.

Authors:  Erik W Faria; Daryl L Parker; Irvin E Faria
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

3.  Correlations between physiological variables and performance in high level cross country off road cyclists.

Authors:  F M Impellizzeri; S M Marcora; E Rampinini; P Mognoni; A Sassi
Journal:  Br J Sports Med       Date:  2005-10       Impact factor: 13.800

4.  Power output during women's World Cup road cycle racing.

Authors:  Tammie R Ebert; David T Martin; Warren McDonald; James Victor; John Plummer; Robert T Withers
Journal:  Eur J Appl Physiol       Date:  2005-09-06       Impact factor: 3.078

Review 5.  The physiology of mountain biking.

Authors:  Franco M Impellizzeri; Samuele M Marcora
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

6.  Level ground and uphill cycling ability in elite female mountain bikers and road cyclists.

Authors:  F M Impellizzeri; T Ebert; A Sassi; P Menaspà; E Rampinini; D T Martin
Journal:  Eur J Appl Physiol       Date:  2007-10-18       Impact factor: 3.078

Review 7.  The science of cycling: physiology and training - part 1.

Authors:  Erik W Faria; Daryl L Parker; Irvin E Faria
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

8.  The upper limit of aerobic power in humans.

Authors:  Martin Burtscher; Werner Nachbauer; Randall Wilber
Journal:  Eur J Appl Physiol       Date:  2011-03-04       Impact factor: 3.078

9.  Bone loss over 1 year of training and competition in female cyclists.

Authors:  Vanessa D Sherk; Daniel W Barry; Karen L Villalon; Kent C Hansen; Pamela Wolfe; Wendy M Kohrt
Journal:  Clin J Sport Med       Date:  2014-07       Impact factor: 3.638

Review 10.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.